Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Michelsen, Brigitte ; Østergaard, Mikkel ; Nissen, Michael John ; Ciurea, Adrian ; Möller, Burkhard ; Ørnbjerg, Lykke Midtbøll ; Zavada, Jakub ; Glintborg, Bente ; MacDonald, Alan and Laas, Karin , et al. (2023) In The Lancet Regional Health - Europe 33.
Abstract

This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied... (More)

This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Axial spondyloarthritis, Health policy, Psoriatic arthritis, Treatment recommendations
in
The Lancet Regional Health - Europe
volume
33
article number
100706
publisher
Elsevier
external identifiers
  • scopus:85166759844
  • pmid:37601339
ISSN
2666-7762
DOI
10.1016/j.lanepe.2023.100706
language
English
LU publication?
yes
id
72388050-d6d1-4f22-bd9a-0fb1d3ec2cf3
date added to LUP
2023-10-24 11:41:23
date last changed
2025-01-11 05:55:05
@article{72388050-d6d1-4f22-bd9a-0fb1d3ec2cf3,
  abstract     = {{<p>This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.</p>}},
  author       = {{Michelsen, Brigitte and Østergaard, Mikkel and Nissen, Michael John and Ciurea, Adrian and Möller, Burkhard and Ørnbjerg, Lykke Midtbøll and Zavada, Jakub and Glintborg, Bente and MacDonald, Alan and Laas, Karin and Nordström, Dan and Gudbjornsson, Bjorn and Iannone, Florenzo and Hellmand, Pasoon and Kvien, Tore Kristian and Rodrigues, Ana Maria and Codreanu, Catalin and Rotar, Ziga and Castrejón Fernández, Isabel and Wallman, Johan Karlsson and Vencovsky, Jiri and Loft, Anne Gitte and Heddle, Maureen and Vorobjov, Sigrid and Hokkanen, Anna Mari and Gröndal, Gerdur and Sebastiani, Marco and van de Sande, Marleen and Kristianslund, Eirik Klami and Santos, Maria José and Mogosan, Corina and Tomsic, Matija and Díaz-González, Federico and Di Giuseppe, Daniela and Hetland, Merete Lund}},
  issn         = {{2666-7762}},
  keywords     = {{Axial spondyloarthritis; Health policy; Psoriatic arthritis; Treatment recommendations}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{The Lancet Regional Health - Europe}},
  title        = {{Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe}},
  url          = {{http://dx.doi.org/10.1016/j.lanepe.2023.100706}},
  doi          = {{10.1016/j.lanepe.2023.100706}},
  volume       = {{33}},
  year         = {{2023}},
}